Tamsulosin ups IFIS risk by more than 50%

Article

Tamsulosin increases the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery by more than 50%, according to results of a study published online ahead of print by Acta Ophthalmologica.

Tamsulosin increases the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery by more than 50%, according to results of a study published online ahead of print by Acta Ophthalmologica.

Ugur Keklikçi, MD of the Department of Ophthalmology in the Faculty of Medicine, Dicle University, Diyarbakir, Turkey and colleagues conducted a non-randomized, observational study of eyes (n=594) undergoing cataract surgery.

Of the 23 patients taking tamsulosin, 52% (n=12) displayed symptoms of IFIS: this accounted for 80% of all the eyes that developed IFIS (n=15). The odds ratio of IFIS development after tamsulosin use was 206.5; the risk ratio was 99.3. No other variable (age, duration of tamsulosin use etc) was found to influence the likelihood of IFIS development.

The researchers concluded that tamsulosin use significantly increases the likelihood of IFIS development, and that the duration of this usage is irrelevant.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.